Evidence map›Paper›PMID 32386967›Full record

ArticleKidney international2020

Selective nanoparticle-mediated targeting of renal tubular Toll-like receptor 9 attenuates ischemic acute kidney injury.

Sang Jun Han, Ryan M Williams, Vivette D'Agati, Edgar A Jaimes, Daniel A Heller, H Thomas Lee

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions.Journal of the American Society of Nephrology : JASN · 2025
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sang Jun HanDepartment of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York, USA.
Ryan M WilliamsDepartment of Molecular Pharmacology & Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Biomedical Engineering, City College of New York, New York, New York, USA.
Vivette D'AgatiDepartment of Pathology, College of Physicians and Surgeons of Columbia University, New York, New York, USA.
Edgar A JaimesRenal Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Daniel A HellerDepartment of Molecular Pharmacology & Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
H Thomas LeeDepartment of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York, USA. Electronic address: tl128@columbia.edu.
Columbia University · USMemorial Sloan Kettering Cancer Center · USCity College of New York · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor MicroenvironmentR01CA215719 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2018 to 2022
$3.1M
Paneth cells and acute kidney injuryR01DK109544 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LEE, H. THOMAS · 2017 to 2021
$1.8M
Peptidylarginine deiminase-4 and acute kidney injuryR01DK115694 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LEE, H. THOMAS · 2017 to 2021
$1.6M
Renal tubule-specific nanotherapeutics for acute kidney injuryR01DK114321 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN, JAIMES, EDGAR A · 2018 to 2020
$796k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA215719NIDDK NIH HHS R01 DK109544NIDDK NIH HHS R01 DK114321NIDDK NIH HHS R01 DK115694
6 · The paper itself

Abstract

We developed an innovative therapy for ischemic acute kidney injury with discerning kidney-targeted delivery of a selective Toll-like receptor 9 (TLR9) antagonist in mice subjected to renal ischemia reperfusion injury. Our previous studies showed that mice deficient in renal proximal tubular TLR9 were protected against renal ischemia reperfusion injury demonstrating a critical role for renal proximal tubular TLR9 in generating ischemic acute kidney injury. Herein, we used 300-400 nm polymer-based mesoscale nanoparticles that localize to the renal tubules after intravenous injection. Mice were subjected to sham surgery or 30 minutes renal ischemia and reperfusion injury after receiving mesoscale nanoparticles encapsulated with a selective TLR9 antagonist (unmethylated CpG oligonucleotide ODN2088) or mesoscale nanoparticles encapsulating a negative control oligonucleotide. Mice treated with the encapsulated TLR9 antagonist either six hours before renal ischemia, at the time of reperfusion or 1.5 hours after reperfusion were protected against ischemic acute kidney injury. The ODN2088-encapsulated nanoparticles attenuated renal tubular necrosis, inflammation, decreased proinflammatory cytokine synthesis. neutrophil and macrophage infiltration and apoptosis, decreased DNA fragmentation and caspase 3/8 activation when compared to the negative control nanoparticle treated mice. Taken together, our studies further suggest that renal proximal tubular TLR9 activation exacerbates ischemic acute kidney injury by promoting renal tubular inflammation, apoptosis and necrosis after ischemia reperfusion. Thus, our studies suggest a potential promising therapy for ischemic acute kidney injury with selective kidney tubular targeting of TLR9 using mesoscale nanoparticle-based drug delivery.

Indexed as

Acute Kidney InjuryNanoparticlesReperfusion InjuryAnimalsApoptosisIschemiaKidneyKidney Tubules, ProximalMiceMice, Inbred C57BLToll-Like Receptor 9Tlr9 protein, mouseToll-Like Receptor 9apoptosisinflammationischemia and reperfusion injurymesoscale nanoparticlenecrosisneutrophil

Identifiers

PMID32386967
PMCPMC7872414
OpenAlexW3007722859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.